Compare GKOS & WING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GKOS | WING |
|---|---|---|
| Founded | 1998 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9B | 6.7B |
| IPO Year | 2015 | 2015 |
| Metric | GKOS | WING |
|---|---|---|
| Price | $103.96 | $211.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 28 |
| Target Price | $133.07 | ★ $338.78 |
| AVG Volume (30 Days) | 662.2K | ★ 1.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 0.55% |
| EPS Growth | N/A | ★ 67.84 |
| EPS | N/A | ★ 6.21 |
| Revenue | $507,442,000.00 | ★ $696,853,000.00 |
| Revenue This Year | $23.39 | $18.23 |
| Revenue Next Year | $27.46 | $16.31 |
| P/E Ratio | ★ N/A | $35.41 |
| Revenue Growth | ★ 32.33 | 11.35 |
| 52 Week Low | $73.16 | $204.09 |
| 52 Week High | $130.23 | $388.14 |
| Indicator | GKOS | WING |
|---|---|---|
| Relative Strength Index (RSI) | 35.28 | 35.54 |
| Support Level | $81.54 | N/A |
| Resistance Level | $106.52 | $271.21 |
| Average True Range (ATR) | 3.58 | 12.90 |
| MACD | -1.81 | -4.10 |
| Stochastic Oscillator | 14.28 | 2.58 |
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Founded in 1994 in Garland, Texas, Wingstop is a restaurant operator specializing in indulgent bone-in and boneless chicken wings, chicken tenders, fries, and, recently, chicken sandwiches. The firm's footprint has grown quickly since its inception, expanding to 2,932 global stores at the end of the third quarter of 2025. With a 98% franchised model, Wingstop generates the lion's share of its revenue from franchise royalties and advertising fees, with the remainder derived from a small footprint of company-owned stores.